Bud Selig

Bud Selig issues his official statement on the Biogenesis suspensions

68 Comments

If there was ever a time for this pic, it’s now.

source: Reuters

Bud’s official statement:

“Major League Baseball has worked diligently with the Players Association for more than a decade to make our Joint Drug Program the best in all of professional sports.  I am proud of the comprehensive nature of our efforts – not only with regard to random testing, groundbreaking blood testing for human Growth Hormone and one of the most significant longitudinal profiling programs in the world, but also our investigative capabilities, which proved vital to the Biogenesis case.  Upon learning that players were linked to the use of performance-enhancing drugs, we vigorously pursued evidence that linked those individuals to violations of our Program.  We conducted a thorough, aggressive investigation guided by facts so that we could justly enforce our rules.

“Despite the challenges this situation has created during a great season on the field, we pursued this matter because it was not only the right thing to do, but the only thing to do.  For weeks, I have noted the many players throughout the game who have strongly voiced their support on this issue, and I thank them for it.  I appreciate the unwavering support of our owners and club personnel, who share my ardent desire to address this situation appropriately.  I am also grateful to the Professional Baseball Athletic Trainers Society and our club physicians, who were instrumental in the banning of amphetamines and whose expertise remains invaluable to me.  As an institution, we have made unprecedented strides together.

“It is important to point out that 16,000 total urine and blood tests were conducted on players worldwide under MLB Drug Programs in 2012.  With the important additions of the hGH testing and longitudinal profiling this season, we are more confident than ever in the effectiveness of the testing program.  Those players who have violated the Program have created scrutiny for the vast majority of our players, who play the game the right way.

“This case resoundingly illustrates that the strength of our Program is not limited only to testing.  We continue to attack this issue on every front – from science and research, to education and awareness, to fact-finding and investigative skills.  Major League Baseball is proud of the enormous progress we have made, and we look forward to working with the players to make the penalties for violations of the Drug Program even more stringent and a stronger deterrent.

“As a social institution with enormous social responsibilities, Baseball must do everything it can to maintain integrity, fairness and a level playing field.  We are committed to working together with players to reiterate that performance-enhancing drugs will not be tolerated in our game.”

Jake Diekman will miss at least half of the 2017 season

TORONTO, ON - OCTOBER 9: Jake Diekman #41 of the Texas Rangers works against the Toronto Blue Jays in the sixth inning during game three of the American League Division Series at Rogers Centre on October 9, 2016 in Toronto, Canada. (Photo by Tom Szczerbowski/Getty Images)
Tom Szczerbowski/Getty Images
Leave a comment

Rangers reliever Jake Diekman will have surgery on January 25 to help alleviate ulcerative colitis, an inflammatory bowel disease. As a result, the lefty will miss at least half of the 2017 regular season, Jeff Wilson of the Fort Worth Star-Telegram reports. Diekman was diagnosed with the illness when he was 11 years old. He has brought awareness to the Crohn’s and Colitis Foundation of America with a “Gut It Out” campaign.

Diekman, who turns 30 years old on Saturday, finished the 2016 campaign with a 3.40 ERA and a 59/26 K/BB ratio in 53 innings. He came to the Rangers from the Phillies in the Cole Hamels trade on July 31, 2015.

The Rangers and Diekman avoided arbitration last Friday, agreeing to a $2.55 million salary for the 2017 season.

The Blue Jays and Bautista have reached a one year deal

TORONTO, ON - OCTOBER 19:  Jose Bautista #19 of the Toronto Blue Jays looks on during batting practice prior to game five of the American League Championship Series against the Cleveland Indians at Rogers Centre on October 19, 2016 in Toronto, Canada.  (Photo by Vaughn Ridley/Getty Images)
Getty Images
2 Comments

It’s been on the verge of happening for a few days now, but now it’s official: the Toronto Blue Jays and Jose Bautista have reached a one-year deal with a mutual option. The deal is pending physical. An announcement making the deal official is expected later in week.

The exact financial figures have not been disclosed, but Jon Heyman reports that it will be in excess of the $17.2 million Bautista turned down when he turned down the Jays’ qualifying offer.

Bautista had a tough 2016, hitting .234/.366/.452 with 22 home runs and 69 RBI, and some clubs likely considered a long-term deal for the 36-year-old too risky, this leading to the relative lack of reported interest in Bautista by other clubs. But back-to-back ALCS appearances by the Jays and the success and popularity Bautista has experienced in Toronto make his re-signing there a pretty sensible move for all involved.